A prospective, multicenter study to evaluate the efficacy and safety of adding obinutuzumab (O-triple) to standard therapy consisting of mycophenolate mofetil (MMF) and glucocorticoids as an initial treatment regimen for patients with active lupus nephritis.

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 08fa281559e772005ab0b9317fb89e42979cabe2
First added on: Oct 10, 2026